1 week ago
9
MarketBeat
Fri, August 7, 2026 astatine 11:04 AM CDT 7 min read
Key Points
-
Interested successful Canopy Growth Corporation? Here are 5 stocks we similar better.
-
Canopy Growth's fiscal Q1 2027 gross roseate 13% to C$81.2 million, with year-over-year maturation crossed its cannabis and Storz & Bickel businesses. Adjusted EBITDA nonaccomplishment narrowed 59% to C$3.2 million, and absorption reiterated its people of achieving affirmative adjusted EBITDA during fiscal 2027.
-
Cannabis gross accrued 14%, led by 22% maturation successful Canadian aesculapian cannabis and 10% maturation successful some adult-use and planetary markets. The institution expects U.K. angiosperm shipments to statesman soon, with gross contributions anticipated successful the 2nd fractional of fiscal 2027.
-
Management is prioritizing cultivation improvements, supply-chain efficiencies and MTL Cannabis synergies to grow margins. Adjusted consolidated gross borderline improved to 31%, portion Canopy is targeting mid-30% margins successful the adjacent word and is executing against C$8 cardinal of annualized MTL synergies.
-
The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock Valuations
Canopy Growth (NASDAQ:CGC) reported first-quarter fiscal 2027 nett gross of C$81.2 million, up 13% from the prior-year period, arsenic the institution recorded year-over-year maturation crossed its cannabis and Storz & Bickel businesses.
Chief Executive Officer Luc Mongeau said the 4th marked the archetypal clip since helium joined the institution successful January 2025 that Canopy reported year-over-year maturation successful each of its concern lines. He attributed the advancement to efforts undertaken during fiscal 2026 to sharpen operations, trim costs and integrate MTL Cannabis, which Canopy acquired successful March.
→ Meta's Earnings Drop Shows Wall Street Wants More Than Ad Growth
-
Constellation Brands: A Fallen Star oregon a Hidden Value Play?
"Fiscal 2027 is astir maturation and moving our absorption to cultivation to amended yields and accelerate growth, particularly successful Europe," Mongeau said. He added that the institution is besides expanding manufacturing efforts to amended margins and beforehand toward affirmative adjusted EBITDA.
Revenue Growth Across Cannabis Channels
Canopy's cannabis conception grew 14% twelvemonth implicit twelvemonth during the quarter. Canadian aesculapian cannabis gross roseate 22% to C$25.8 million, driven by an summation successful diligent counts implicit the past year. The concern has been expanded done MTL Cannabis' Canada House clinics and Abba Medix online organisation platform.
→ 4 Oil and Gas ETF Plays arsenic Prices Stay Sky-High
-
Profit from the Green Wave: Top Cannabis Stocks to Watch
Mongeau said Canopy continued to adhd patients and summation the fig of orders filled during the quarter, supporting its presumption arsenic the largest Canadian aesculapian cannabis provider. He noted, however, that the institution has been affected by reduced reimbursement rates from Veterans Affairs Canada, fixed its absorption connected seasoned care.
English (CA) · 
English (US) · 
Spanish (MX) ·